Home > News > Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
October 19th, 2004
Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that Insert is planning with City of Hope Comprehensive Cancer Center a broad-based Phase I clinical trial for Insert's lead drug candidate.
Source:
businesswire
Related Links |
Arrowhead Research Corporation
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||